Cellectis CLLS Stock
Cellectis Price Chart
Cellectis CLLS Financial and Trading Overview
| Cellectis stock price | 2.69 USD |
| Previous Close | 1.98 USD |
| Open | 2.01 USD |
| Bid | 0 USD x 3000 |
| Ask | 0 USD x 900 |
| Day's Range | 2 - 2.04 USD |
| 52 Week Range | 1.68 - 4.1 USD |
| Volume | 38.02K USD |
| Avg. Volume | 63.99K USD |
| Market Cap | 117.25M USD |
| Beta (5Y Monthly) | 2.026819 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.41 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.8 USD |
CLLS Valuation Measures
| Enterprise Value | 107.96M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.4676259 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.6011553 |
| Price/Book (mrq) | 0.99706745 |
| Enterprise Value/Revenue | 4.237 |
| Enterprise Value/EBITDA | -1.473 |
Trading Information
Cellectis Stock Price History
| Beta (5Y Monthly) | 2.026819 |
| 52-Week Change | -24.16% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.1 USD |
| 52 Week Low | 1.68 USD |
| 50-Day Moving Average | 1.91 USD |
| 200-Day Moving Average | 2.33 USD |
CLLS Share Statistics
| Avg. Volume (3 month) | 63.99K USD |
| Avg. Daily Volume (10-Days) | 39.44K USD |
| Shares Outstanding | 55.58M |
| Float | 39.38M |
| Short Ratio | 4.61 |
| % Held by Insiders | 12.13% |
| % Held by Institutions | 16.70% |
| Shares Short | 309.21K |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 0.55% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -327.15% |
| Gross Margin | 93.24% |
| EBITDA Margin | -287.60% |
Management Effectiveness
| Return on Assets (ttm) | -17.40% |
| Return on Equity (ttm) | -60.70% |
Income Statement
| Revenue (ttm) | 25.48M USD |
| Revenue Per Share (ttm) | 0.54 USD |
| Quarterly Revenue Growth (yoy) | -6.29% |
| Gross Profit (ttm) | 23.95M USD |
| EBITDA | -73291000 USD |
| Net Income Avi to Common (ttm) | -90707000 USD |
| Diluted EPS (ttm) | -1.9 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 83.52M USD |
| Total Cash Per Share (mrq) | 1.5 USD |
| Total Debt (mrq) | 74.11M USD |
| Total Debt/Equity (mrq) | 61.51 USD |
| Current Ratio (mrq) | 2.272 |
| Book Value Per Share (mrq) | 2.046 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -79158000 USD |
| Levered Free Cash Flow (ttm) | -41880876 USD |
Profile of Cellectis
| Country | United States |
| State | N/A |
| City | Paris |
| Address | 8, rue de la Croix Jarry |
| ZIP | 75013 |
| Phone | 33 1 81 69 16 00 |
| Website | https://www.cellectis.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 231 |
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia Therapeutics. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Q&A For Cellectis Stock
What is a current CLLS stock price?
Cellectis CLLS stock price today per share is 2.69 USD.
How to purchase Cellectis stock?
You can buy CLLS shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cellectis?
The stock symbol or ticker of Cellectis is CLLS.
Which industry does the Cellectis company belong to?
The Cellectis industry is Biotechnology.
How many shares does Cellectis have in circulation?
The max supply of Cellectis shares is 75.56M.
What is Cellectis Price to Earnings Ratio (PE Ratio)?
Cellectis PE Ratio is now.
What was Cellectis earnings per share over the trailing 12 months (TTM)?
Cellectis EPS is -1.41 USD over the trailing 12 months.
Which sector does the Cellectis company belong to?
The Cellectis sector is Healthcare.
Cellectis CLLS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}